Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 70686 [2016-24786]
Download as PDF
<![CDATA[
Lhorne on DSK30JT082PROD with NOTICES
70686
Federal Register / Vol. 81, No. 198 / Thursday, October 13, 2016 / Notices
the webcast can access information at:
https://
cdclabtraining.adobeconnect.com/
novembercliac/.
Online Registration Required: All
people attending the CLIAC meeting inperson are required to register for the
meeting online at least 5 business days
in advance for U.S. citizens and at least
10 business days in advance for
international registrants. Register at:
https://wwwn.cdc.gov/cliac/Meetings/
MeetingDetails.aspx. Register by
scrolling down and clicking the
‘‘Register for this Meeting’’ button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than October 27, 2016 for U.S.
registrants and October 20, 2016 for
international registrants.
Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item.
Oral Comments: In general, each
individual or group requesting to make
oral comments will be limited to a total
time of five minutes (unless otherwise
indicated). Speakers must also submit
their comments in writing for inclusion
in the meeting’s Summary Report. To
assure adequate time is scheduled for
public comments, speakers should
notify the contact person below at least
one week prior to the meeting date.
Written Comments: For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least one week prior to the meeting
date so that the comments may be made
available to the Committee for their
consideration and public distribution.
Written comments, one hard copy with
original signature, should be provided
to the contact person at the mailing or
email address below, and will be
included in the meeting’s Summary
Report.
Availability of Meeting Materials: To
support the green initiatives of the
federal government, the CLIAC meeting
materials will be made available to the
Committee and the public in electronic
format (PDF) on the internet instead of
by printed copy. Check the CLIAC Web
site on the day of the meeting for
materials: https://wwwn.cdc.gov/cliac/
Meetings/MeetingDetails.aspx. Note: If
using a mobile device to access the
materials, please verify that the device’s
VerDate Sep<11>2014
14:07 Oct 12, 2016
Jkt 241001
browser is able to download the files
from the CDC’s Web site before the
meeting.
Alternatively, the files can be
downloaded to a computer and then
emailed to the portable device. An
internet connection, power source, and
limited hard copies may be available at
the meeting location, but cannot be
guaranteed.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329; telephone (404)
498–2741; or via email at NAnderson@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for Centers for
Disease Control and Prevention and the
Agency for Toxic Substances and
Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Office, CDC, pursuant to Public Law 92–
463.
Matters For Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘PAR14–227, Workers’ Compensation
Surveillance, PAR14–227.’’
Contact Person For More Information:
Michael Goldcamp, Ph.D., Scientific
Review Officer, CDC, 1095 Willowdale
Road, Morg Building H, Room 1806,
Mailstop 1808, Morgantown, WV 26506,
Telephone: (304) 285–5951, EHG8@
CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–24786 Filed 10–12–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2016–24785 Filed 10–12–16; 8:45 am]
Office of the Director, National
Institutes of Health; Notice of Closed
Meeting
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) PAR14–227, Workers’
Compensation Surveillance.
Time and Date:
1:00 p.m.–6 p.m., EST, November 9,
2016 (Closed)
Place: Teleconference
Status: The meeting will be closed to
the public in accordance with
provisions set forth in section 552b(c)(4)
and (6), title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Scientific and
Technical Review Board on Biomedical and
Behavioral Research Facilities.
Date: November 9, 2016.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ross D. Shonat, Ph.D.,
Scientific Review Officer, Center for
E:\FR\FM\13OCN1.SGM
13OCN1
]]>Agencies
[Federal Register Volume 81, Number 198 (Thursday, October 13, 2016)]
[Notices]
[Page 70686]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24786]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Funding Opportunity Announcement (FOA)
PAR14-227, Workers' Compensation Surveillance.
Time and Date:
1:00 p.m.-6 p.m., EST, November 9, 2016 (Closed)
Place: Teleconference
Status: The meeting will be closed to the public in accordance with
provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and
the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters For Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``PAR14-227, Workers' Compensation Surveillance, PAR14-227.''
Contact Person For More Information: Michael Goldcamp, Ph.D.,
Scientific Review Officer, CDC, 1095 Willowdale Road, Morg Building H,
Room 1806, Mailstop 1808, Morgantown, WV 26506, Telephone: (304) 285-
5951, EHG8@CDC.GOV.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-24786 Filed 10-12-16; 8:45 am]
BILLING CODE 4163-18-P
